FutuRx Portfolio

Discovering and developing innovative microbiome-based therapeutics to prevent and treat cancer, IBD, and topical diseases that stem from dysbiosis.

Bsense Bio Therapeutics is developing small molecules for the treatment of neuropathic pain. Bsense is pioneering a novel approach targeting multiple pain-related mechanisms using a single compound, to achieve greater efficacy and safety.

GliXogen Therapeutics is developing a treatment to enhance remyelination in neurodegenerative disorders which are driven by damage to the neuron’s myelin sheath, such as multiple sclerosis (MS).

ImmPACT-Bio is pioneering a novel strategy to surmount a major challenge compromising current Chimeric Antigen Receptor T-cell (CAR-T) therapy.

MabTrix is a preclinical stage biopharmaceutical company aiming to develop an innovative, function-blocking therapeutic monoclonal antibody (MAb) for inflammatory bowel disease (IBD) as the initial indication

Mitoconix Bio Ltd is pioneering a novel strategy to improving mitochondrial health as a disease-modifying therapeutic for neurodegenerative diseases

MOYA Bio is developing a novel class of tumor immune conditioning agents. The company’s first-in-class inhibitors of the FAT10 pathway are envisioned to increase the impact of immunotherapy by sensitizing the tumor to immune-mediated cytotoxicity, to benefit additional patient populations.

Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug.

PiNK Biopharma is developing a novel immuno-oncology approach based on a novel NK checkpoint.

Protekt Therapeutics is a biopharmaceutical company aiming to develop a drug for enhancing the long-term memory of those suffering from mild cognitive impairment (MCI)

GENERAL Ramino-Bio is developing treatments for metabolic diseases by enhancing branched chain amino acids (BCAAs; Valine, leucine, and Isoleucine) catabolism. Diet, obesity, genetics and gut microbiota can increase circulating BCAAs above the normal level.  Chronic elevated levels of circulating BCAAs are known to be a causal factor for hepatic lipid storage, muscle lipid accumulation, and […]

TNIK Therapeutics target cancer stem cell diseases by developing small molecule inhibitors of TNIK, the most downstream transcription regulator of the Wnt pathway that is a major force driving colorectal carcinogenesis when over activated.

XoNovo is a biopharmaceutical company developing proprietary small molecules for the treatment of neurodegenerative diseases